Good to you, morning Tony. Thank everyone.
QX first of grew $XXX performance million outstanding. Our quarter Record revenues XX%. was
double-digit $XXX the EBITDA to profits. the QX adjusted grew quarter. million drive growth of in strong For all sustainably segments time, first execution of same XX%, X by as of levels continues higher generated our
confident and Amneal, As to XXXX for are momentum achieve across commitments in builds beyond. our financial ability we our
Our Amneal is payers a provides high-quality, company, be strategic vision pharmaceutical affordable patients, and to access with for essential global, that medicines. providers diversified and to
complex the topicals, medicines, Amneal United XXX provide approximately prescriptions such year. In In ophthalmics. we pharmacies, as fills per transdermals, and oral retail solids million States, generics
medicines. medicines we adding high-quality access in supply to care distribution there acute biosimilars, and specialty, where to veterans our Parkinson's health provide our For In hospitals and portfolio. clinics, military with disease. we the chronic more innovative are care, access our therapies important advanced of oncology shortages. care business, such to injectables, In we expanding In standard are as
in we are needs developing developed and countries. addressing Globally, health unmet care
and of significant to a Amneal is having impact. leading continue new affordable era we larger, a grow societal As medicines
Opioid commitment our U.S. remains a naloxone. health overdose recent Nowhere evident of mission care our emergency. to public more approval than in this
with United as and through States. for and cities rescue product the to the expanding an critical with across states to our the to pleased medicine are finalize We interest, of come. public access partnership OTC more California, We this were at pharmacies state
essential in is by made are proud and Amneal. this here that We New so manufacturing life-saving Jersey in medicine America
Let at ability well where growth to our execute business and in our level, and impact. walk me a confident have remain our to the we drive strategy, tremendous now a through opportunity high
First, our affordable XXXX. which since Generics grown year our medicines business, has segment, is each consistently
are XXXX, in growth driven our We retail, seeing accelerate portfolio injectables and diverse by of biosimilars. this
perpetual track durability Those well regular driving by our a complex affordable of launches record position has plagued to customer the leadership new continue resonate continue and to supply Amneal shortages growth. long-term sustainable and demand hallmarks with in market, high-quality of medicines innovation portfolio for each position in Amneal medicines. year service. U.S. cadence pharmaceutical and The our expanding quality, of
the In XXX to inspections shortages our injectables, retail and and significant lower in to discontinuations, is complex remains States help hospitals has than in supply portfolio market, United and diversified, medicines around we In portfolio industry drug with disruption industry-wide our price due clinics. site of in are pharmaceutical several a the erosion manufacturer years. generic address have been capacity and expanding chain it
products unique to last cancers. launch of the year. XX our track strategy XX record, on PEMRYDI this certain new RTU launch like of following are treatment recent we injectable products on ready-to-use focuses launches year, injectables, lung Our retail our providing for over and new Across
biologics in annual of In estimated branded $XXX the biosimilars, value wave XXXX, we From exclusivity. next are medicines. to lose will billion XXXX seeing an affordable
the rates We them required oncology, operate. we XX%, investment biosimilar are particularly to expect less these biosimilars be of molecules Adoption early bring in markets market. complexities competitive, most to now inherent where the for and to given
networks. delivery adoption strong driving and gives hospital-integrated our pipeline coupled us That, confidence Our excellent is continued trusted team and commercial both momentum. with at partners, with oncology community
with in X be well revenue to We each in to year million or X and $XX biosimilars $XXX over XX integrated in-license our on more over of achieving way are biosimilars vertically over million to We to last time. revenue months. 'XX, look the
Internationally, and critical a geographies, register needs, for Amneal happening select we in working to portfolio ophthalmology, continue products. In with other is and building care, partners and where to most foundation. commercialize strong we'll This expand notably of reach therapies our India, customized are we diagnostics. oncology unmet build are a like
that. We million expect million $XX in by rapidly expansion to $XXX international after will revenues and scale add XXXX
and good Parkinson's to disease, progress Next, make neurology specialty as in-licensed we objective QX, which we our successfully our launched revenues double digits. an for key with recently products portfolio. we In specialty our business, to endocrinology-branded therapy in continue ONGENTYS, growing are
is on IPXXXX, up with action date X. Next August our is
patients. Carbidopa have In we business, IPXXXX has believe doubled our advances revenues distribution care We been care for and XXXX. disease our over Parkinson's all meaningfully for health the acquisition more with application profit standard main for decades. X a broad therapy since than that of in
In dose. We million products and care revenue XXXX to we health this distribution, over as Driven all momentum. in remain unit channels, are from very are now suppliers, starting we $XXX new X expect expect including by with a strong high-growth government short, expanding Amneal, next we business. year
is accelerating remarkably. sustainable our and Our diversified performance profile is growth financial
Chintu. to it hand now I'll
